샘플 요청 목록

 카트 문의
시장보고서
상품코드
1737301

세계의 종양용해성 바이러스 면역요법 시장

Oncolytic Virus Immunotherapy
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 383 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

종양용해성 바이러스 면역요법 세계 시장은 2030년까지 4억 2,910만 달러에 달할 전망

2024년에 1억 5,680만 달러로 추정되는 종양용해성 바이러스 면역요법 세계 시장은 2030년에는 4억 2,910만 달러에 달하고, 분석 기간인 2024-2030년 CAGR은 18.3%로 성장할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 단순포진바이러스는 CAGR 18.6%를 기록하며 분석 기간 종료시에는 1억 8,970만 달러에 달할 것으로 예측됩니다. 백신 바이러스 부문의 성장률은 분석 기간 동안 CAGR 15.3%로 추정됩니다.

미국 시장은 4,270만 달러로 추정, 중국은 CAGR 24.8%로 성장 예측

미국의 종양용해성 바이러스 면역요법 시장은 2024년에 4,270만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간 2024년부터 2030년까지 CAGR 24.8%를 더듬어, 2030년에는 예측 시장 규모 9,970만 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 14.5%와 16.3%로 예측됩니다. 유럽에서는 독일이 CAGR 약 15.2%로 성장할 것으로 예측됩니다.

세계의 종양용해성 바이러스 면역요법 시장 - 주요 동향과 촉진요인 정리

암 면역치료에서 암 용해성 바이러스가 암 면역치료의 파괴적 양식으로 다시 부상하고 있는 이유는 무엇일까?

종양용해성 바이러스 면역요법은 직접적인 종양 용해와 면역 체계의 프라이밍을 결합한 이중 작용 치료 전략으로 종양학에서 다시 한 번 각광을 받고 있습니다. 이러한 유전자 조작 또는 자연 발생 바이러스는 종양 세포를 선택적으로 감염 및 복제하여 종양 세포를 파괴하는 동시에 항암 면역 반응을 자극하는 종양 관련 항원을 방출합니다. 기존의 화학요법이나 방사선 치료와 달리 종양 용해 바이러스는 종양 부위에 국소적으로 작용하고 면역 활성화를 통해 전신적으로 작용하기 때문에 고형 및 혈액 악성 종양 모두에서 범용성이 높은 약제로 자리매김하고 있습니다.

1990년대 초의 좌절에도 불구하고 최근 분자 바이러스학, 유전자 편집 및 면역 종양학의 발전으로 인해 이 접근법에 대한 관심이 다시 높아지고 있습니다. 2015년 흑색종에 대한 T-VEC(talimogene laherparepvec)의 FDA 승인은 획기적인 사건으로, 종양 바이러스 치료의 개념이 임상에서 검증되었습니다. 이후 교모세포종, 대장암, 췌장암, 비소세포폐암 등 여러 암종에 대한 임상시험이 급증하면서 치료법의 범위와 신뢰성이 확대되었습니다. 단독요법 또는 체크포인트 억제제와의 병용요법으로 온코라이트 바이러스는 차세대 면역치료 요법의 핵심이 되고 있습니다.

유전공학과 병용 프로토콜은 어떻게 암 용해성 바이러스 치료의 가능성을 넓히고 있는가?

최근 합성생물학 및 벡터 공학의 획기적인 발전으로 암 용해 바이러스의 안전성, 선택성 및 면역 활성화 능력이 크게 향상되었습니다. 단순포진바이러스(HSV), 아데노 바이러스, 백시니아 바이러스, 레오 바이러스 등을 기반으로 한 새로운 바이러스 구조는 GM-CSF, 인터류킨, 체크포인트 차단 펩타이드 등의 면역 강화 도입 유전자로 무장하고 있습니다. 이러한 변형을 통해 바이러스는 종양 세포를 파괴할 뿐만 아니라 종양미세환경(TME)을 면역학적으로 활성 부위로 바꿀 수 있습니다.

병용요법은 주요 초점이며, 온콜라이트 바이러스는 내성 메커니즘을 극복하고 전신 항종양 반응을 강화하기 위해 면역관문억제제(항 PD-1/PD-L1 등), CAR-T 요법 또는 방사선 요법과 함께 병용하는 경우가 많습니다. 종양 내 투여법, 용량 증량 프로토콜, 다중 부위 투여 전략은 바이러스의 생체 내 분포를 개선하고 표적 외 효과를 감소시켰습니다. 바이러스의 지속성, 면역침윤, 치료 반응을 실시간으로 모니터링하기 위한 액체 생검 및 영상 바이오마커의 개발도 진행되고 있습니다. 이러한 발전으로 종양용해성 바이러스 치료는 틈새 치료법에서 복합적 암 치료의 틀에 필수적인 요소로 전환되고 있습니다.

어떤 종양 유형과 지역이 암 용해 바이러스의 임상적, 상업적 전망을 형성하고 있는가?

흑색종, 신경교모세포종, 췌장암, 간세포암 등 면역억제성 미세환경을 가진 고형암은 종양용해성 바이러스 치료의 유력한 후보군입니다. 이러한 암은 일반적으로 기존 치료법에 대한 반응성이 낮고 T세포의 침윤이 부족한 경우가 많은데, 종양용해 바이러스는 이를 극복하는 데 도움이 됩니다. 림프종이나 다발성 골수종과 같은 혈액 악성 종양도 자연면역과 적응면역 모두에 작용할 수 있는 인공 바이러스에 의해 표적이 되고 있습니다.

북미가 임상 개발을 주도하고 있으며, 미국이 초기 단계 및 주요 임상시험의 대부분을 수행하고 있습니다. 주요 바이러스 치료제 개발 기업의 존재, 탄탄한 자금 조달 생태계, 혁신 친화적인 규제 환경은 중개적 진전을 가속화하고 있습니다. 유럽은 강력한 산학협력과 EMA의 첨단치료제(ATMP) 지정을 통한 규제적 지원으로 그 뒤를 잇고 있습니다. 아시아태평양은 경쟁 지역으로 부상하고 있으며, 특히 중국에서는 바이오테크 기업들이 온콜로지컬 플랫폼에 많은 투자를 하고 있고, 규제 개혁을 통해 빠른 임상 시작을 가능하게 하고 있습니다. 전 세계 암센터에서는 온콜로틱 바이러스를 컴패니언 사용 프로그램 및 병용 시험 프로토콜에 통합하려는 움직임이 가속화되고 있습니다.

종양용해성 바이러스 면역요법 시장의 장기적인 성장과 과학적 혁신의 원동력은 무엇인가?

종양용해성 바이러스 면역치료제 시장의 성장 동력은 면역 주도형 암 제어로의 패러다임 변화, 난치성 종양 발생률 증가, 유전자 변형 생물학적 제제에 대한 규제 당국의 개방성 증가 등입니다. 암세포 용해 바이러스는 맞춤형 페이로드와 전달 옵션을 갖춘 플랫폼 접근법을 제공하여 진화하는 면역 종양학 환경에 대한 적응성을 높이고 있습니다. 종양을 저온에서 고온으로 전환하는 바이러스의 능력은 오늘날 암 면역치료의 가장 큰 과제 중 하나를 해결하고 있습니다.

제약사들은 학계 바이러스학자, 생명공학 기업, 임상 종양학 네트워크와의 협업을 통해 AI를 활용한 바이러스 벡터 설계, CRISPR을 활용한 도입 유전자 통합, 종양 내 미량 투여 기술을 통해 특이성 및 안전성 프로파일을 향상시키고 있습니다. 프로파일이 향상되고 있습니다. 확장 가능한 제조, 동결건조 제제, 콜드체인 물류에 대한 투자는 보다 광범위한 시장에 대응할 수 있도록 지원하고 있습니다. 맞춤형 암 백신과 면역세포 치료가 대중화됨에 따라 종양용해성 바이러스는 자연면역과 적응면역을 연결하는 면역증폭제 역할을 하고 있습니다. 암 면역치료의 미래는 이러한 프로그램 가능한 자가증폭 및 면역감작 바이러스에 의해 점점 더 많이 형성될 것으로 보입니다.

부문

유형(단순포진바이러스, 백시니아바이러스, 아데노바이러스, 레오바이러스, 기타 유형), 투여 경로(종양내 루트, 정맥내 루트), 용도(흑색종 용도, 비소세포폐암 용도, 췌장암 용도, 유방암 용도, 기타 용도)

조사 대상 기업 사례(총 41개사)

  • Amgen Inc.
  • CG Oncology
  • Creative Biolabs
  • Daiichi Sankyo Co., Ltd.
  • Genelux Corporation
  • ImmVirX
  • Imugene Limited
  • Lokon Pharma AB
  • Merck & Co., Inc.
  • Oncolys BioPharma Inc.
  • Oncolytics Biotech Inc.
  • Oncorus Inc.
  • Replimune Group Inc.
  • SillaJen, Inc.
  • Sorrento Therapeutics, Inc.
  • Syneos Health, Inc.
  • TILT Biotherapeutics Ltd.
  • Transgene S.A.
  • Viralytics Ltd.
  • ViraTherapeutics GmbH

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월 : 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월 : 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석:

미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국

업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.06.12

Global Oncolytic Virus Immunotherapy Market to Reach US$429.1 Million by 2030

The global market for Oncolytic Virus Immunotherapy estimated at US$156.8 Million in the year 2024, is expected to reach US$429.1 Million by 2030, growing at a CAGR of 18.3% over the analysis period 2024-2030. Herpes Simplex Virus, one of the segments analyzed in the report, is expected to record a 18.6% CAGR and reach US$189.7 Million by the end of the analysis period. Growth in the Vaccinia Virus segment is estimated at 15.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$42.7 Million While China is Forecast to Grow at 24.8% CAGR

The Oncolytic Virus Immunotherapy market in the U.S. is estimated at US$42.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$99.7 Million by the year 2030 trailing a CAGR of 24.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.5% and 16.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.2% CAGR.

Global Oncolytic Virus Immunotherapy Market - Key Trends & Drivers Summarized

Why Are Oncolytic Viruses Re-emerging as a Disruptive Modality in Cancer Immunotherapy?

Oncolytic virus immunotherapy is gaining renewed momentum in oncology as a dual-action therapeutic strategy that combines direct tumor lysis with immune system priming. These genetically engineered or naturally occurring viruses selectively infect and replicate in tumor cells, causing their destruction while releasing tumor-associated antigens that stimulate anti-cancer immune responses. Unlike traditional chemotherapy or radiation, oncolytic viruses act locally at the tumor site and systemically through immune activation, positioning them as versatile agents in both solid and hematologic malignancies.

Despite early setbacks in the 1990s, recent advances in molecular virology, gene editing, and immune-oncology have revitalized interest in this approach. The 2015 approval of T-VEC (talimogene laherparepvec) by the FDA for melanoma marked a watershed moment, validating the concept of oncolytic virus therapy in clinical practice. Since then, a surge of clinical trials targeting multiple cancer types-including glioblastoma, colorectal cancer, pancreatic cancer, and non-small cell lung cancer-has expanded the scope and credibility of the modality. As monotherapies and in combination with checkpoint inhibitors, oncolytic viruses are becoming a cornerstone of next-generation immunotherapy regimens.

How Are Genetic Engineering and Combination Protocols Expanding the Potential of Oncolytic Virotherapy?

Recent breakthroughs in synthetic biology and vector engineering are significantly enhancing the safety, selectivity, and immune-stimulatory capabilities of oncolytic viruses. New viral constructs-based on herpes simplex virus (HSV), adenovirus, vaccinia virus, and reovirus-are being armed with immune-boosting transgenes such as GM-CSF, interleukins, or checkpoint blockade peptides. These modifications allow the virus to not only destroy tumor cells but also convert the tumor microenvironment (TME) into an immunologically active site.

Combination therapies are a major focus, with oncolytic viruses increasingly paired with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1), CAR-T therapies, or radiotherapy to overcome resistance mechanisms and enhance systemic anti-tumor responses. Intratumoral delivery methods, dose escalation protocols, and multi-site administration strategies are improving virus biodistribution and reducing off-target effects. Liquid biopsy and imaging biomarkers are being developed to monitor viral persistence, immune infiltration, and treatment response in real time. These advancements are transitioning oncolytic virotherapy from a niche modality into an integral component of multi-modal cancer treatment frameworks.

Which Tumor Types and Geographies Are Shaping the Clinical and Commercial Landscape for Oncolytic Viruses?

Solid tumors with immunosuppressive microenvironments-such as melanoma, glioblastoma, pancreatic cancer, and hepatocellular carcinoma-are prime candidates for oncolytic virotherapy. These cancers typically respond poorly to conventional therapies and often lack T-cell infiltration, which oncolytic viruses can help overcome. Hematologic malignancies like lymphoma and multiple myeloma are also being targeted through engineered viruses capable of engaging both innate and adaptive immunity.

North America leads clinical development, with the U.S. hosting the majority of early-phase and pivotal trials. The presence of major virotherapy developers, robust funding ecosystems, and an innovation-friendly regulatory environment accelerates translational progress. Europe follows with strong academic-industry partnerships and regulatory support through the EMA’s Advanced Therapy Medicinal Product (ATMP) designation. Asia-Pacific is emerging as a competitive landscape, particularly in China, where biotech firms are investing heavily in oncolytic platforms and regulatory reforms are enabling faster trial initiation. Global oncology centers are increasingly integrating oncolytic viruses into compassionate use programs and combination trial protocols.

What Is Powering Long-Term Growth and Scientific Innovation in the Oncolytic Virus Immunotherapy Market?

The growth in the oncolytic virus immunotherapy market is powered by a paradigm shift toward immune-driven cancer control, rising incidence of refractory tumors, and growing regulatory openness to gene-modified biologicals. Oncolytic viruses offer a platform approach with customizable payloads and delivery options, making them highly adaptable to evolving immuno-oncology landscapes. Their ability to initiate cold-to-hot tumor conversion addresses one of the biggest challenges in cancer immunotherapy today.

Pharmaceutical companies are accelerating R&D through collaborations with academic virologists, biotech firms, and clinical oncology networks. AI-driven viral vector design, CRISPR-enabled transgene integration, and intratumoral microdosing techniques are improving specificity and safety profiles. Investment in scalable manufacturing, lyophilized formulations, and cold-chain logistics is supporting broader market readiness. As personalized cancer vaccines and immune cell therapies gain traction, oncolytic viruses are poised to serve as immune amplifiers that bridge innate and adaptive response layers. The future of cancer immunotherapy will be increasingly shaped by these programmable, self-amplifying, and immune-sensitizing viral agents.

SCOPE OF STUDY:

The report analyzes the Oncolytic Virus Immunotherapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus, Other Types); Administration Route (Intratumoral Route, Intravenous Route); Application (Melanoma Application, Non-small Cell Lung Cancer Application, Pancreatic Cancer Application, Breast Cancer Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Amgen Inc.
  • CG Oncology
  • Creative Biolabs
  • Daiichi Sankyo Co., Ltd.
  • Genelux Corporation
  • ImmVirX
  • Imugene Limited
  • Lokon Pharma AB
  • Merck & Co., Inc.
  • Oncolys BioPharma Inc.
  • Oncolytics Biotech Inc.
  • Oncorus Inc.
  • Replimune Group Inc.
  • SillaJen, Inc.
  • Sorrento Therapeutics, Inc.
  • Syneos Health, Inc.
  • TILT Biotherapeutics Ltd.
  • Transgene S.A.
  • Viralytics Ltd.
  • ViraTherapeutics GmbH

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Oncolytic Virus Immunotherapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Precision Oncology Spurs Development of Oncolytic Virus Platforms With Tumor Selectivity
    • Expansion of Immunotherapy Research Pipelines Strengthens Business Case for Oncolytic Virus Modalities
    • Increased Approval of Cancer Immunotherapies Throws the Spotlight on Next-Generation Viral Vectors
    • Breakthrough Designation Status and Fast Track Approvals Accelerate Regulatory Momentum
    • Advancements in Genetic Engineering of Viruses Drive Enhanced Tumor Targeting and Immune Activation
    • Surge in Clinical Trials Combining Oncolytic Viruses With Checkpoint Inhibitors Expands Therapeutic Horizons
    • Increased Use of Oncolytic Viruses as Neoadjuvant Therapies Supports Multimodal Cancer Management
    • Growing Investment From Biopharma and Venture Capital Enhances Innovation and Clinical Translation
    • Development of Tumor-Specific Viral Payloads Strengthens Oncolytic Virus Selectivity and Safety Profiles
    • Adoption of Intratumoral and Systemic Delivery Routes Expands Accessibility to Diverse Tumor Types
    • Improved Understanding of Tumor Microenvironment Enhances Viral Mechanism Optimization
    • Collaborative Efforts Between Academia and Industry Propel Translational Research in Viral Oncology
    • Expansion of Cold Chain Logistics Infrastructure Supports Global Supply of Virus-Based Therapies
    • Public and Philanthropic Funding for Rare Cancer Treatment Drives Orphan Application Development
    • Manufacturing Scale-Up of Viral Vectors Remains a Bottleneck for Commercialization Readiness
    • Development of Immune Response Biomarkers Facilitates Patient Selection and Treatment Monitoring
    • Increased Advocacy for Personalized Cancer Immunotherapy Supports Patient Enrollment in Viral Trials
    • Challenges in Viral Shedding and Immunogenicity Highlight Need for Improved Safety Profiling
    • Rising Global Cancer Incidence and Limited Success in Refractory Cancers Propel Need for Disruptive Modalities
    • Regulatory Alignment on Gene and Virus Therapies Enhances Global Clinical Trial Harmonization
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oncolytic Virus Immunotherapy Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Oncolytic Virus Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Oncolytic Virus Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Herpes Simplex Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Vaccinia Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Vaccinia Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Vaccinia Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Adenovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Adenovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Adenovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Reovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Reovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Reovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pancreatic Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pancreatic Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Pancreatic Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Breast Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Melanoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Melanoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Melanoma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Non-small Cell Lung Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Non-small Cell Lung Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Non-small Cell Lung Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Intratumoral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Intratumoral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Intratumoral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Intravenous Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Intravenous Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Intravenous Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • JAPAN
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • CHINA
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • EUROPE
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Oncolytic Virus Immunotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • FRANCE
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • GERMANY
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • INDIA
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Oncolytic Virus Immunotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Oncolytic Virus Immunotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
  • AFRICA
    • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제